Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) were down 18.6% during mid-day trading on Tuesday . The company traded as low as C$0.04 and last traded at C$0.04. Approximately 546,500 shares were traded during trading, an increase of 614% from the average daily volume of 76,569 shares. The stock had previously closed at C$0.04.
Kane Biotech Price Performance
The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The stock’s fifty day simple moving average is C$0.05 and its 200-day simple moving average is C$0.07. The company has a market capitalization of C$5.04 million, a P/E ratio of 0.88 and a beta of 0.52.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Articles
- Five stocks we like better than Kane Biotech
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Buffett’s Wisdom Could Spell Trouble for Palantir Shorts
- The 3 Best Fintech Stocks to Buy Now
- Petrobras: Why Traders Are Betting Big on a Shareholder Payout
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Tesla Just Had Its Best Day in 2 Months—Here’s What It Means
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
